Feb 21, 2013 by Brenton FlynnCan J&J and Pharmacyclics Help Fix Health Care?Through better patient targeting, our health-care system can also cut costs.
Feb 21, 2013 by Brenton Flynn1 Way Abbott Labs Can Fix Health CareCompanion diagnostics can help patients, while also cutting costs.
Feb 21, 2013 by Brenton FlynnRepros Soars -- and AbbVie Might SufferNew life for Androxal offers hope for Repros.
Feb 21, 2013 by Brenton FlynnIs Intuitive Hedging Its Bets?Does this wording change mean that Intuitive Surgical is finally addressing the bears?
Feb 20, 2013 by Brenton FlynnA Health Insurance Opportunity, Risk, or Both?Why the Affordable Care Act's individual mandate represents both an opportunity and a risk to health care investors.
Feb 20, 2013 by Brenton FlynnQuestcor's Sole OpportunityWhat's the biggest opportunity for Questcor investors today?
Feb 19, 2013 by Brenton FlynnIntuitive Has Its Eye on This NewcomerIs this small cap company a new competitive threat to Intuitive?
Feb 19, 2013 by Brenton FlynnHealth Care's Battle for the MailboxOne big trend Cardinal Health is taking advantage of with this major acquisition.
Feb 19, 2013 by Brenton FlynnUnitedHealth's Annual CheckupTime to take UnitedHealth to the doctor and see how it's doing this year.
Feb 19, 2013 by Brenton FlynnToday, Medicare Advantage Turns Into a DisadvantageThe thought of lower reimbursements for medicare advantage has some managed care companies feeling the pain.
Feb 19, 2013 by Brenton FlynnWhat You Need to Know About Express Scripts' EarningsThe largest pharmacy benefit manager put up better than expected guidance.
Feb 19, 2013 by Brenton FlynnPeregrine Investors: Once Bitten, Twice ShyInvestors aren't too excited about this secondary data analysis
Feb 13, 2013 by Brenton FlynnCan a New CEO Turn This Insurer Around?An outsider to managed care becomes WellPoint's new CEO.
Feb 13, 2013 by Brenton FlynnCan Peregrine Match Celgene? No.Peregrine's latest data can't match that from big biotech Celgene.
Feb 12, 2013 by Brenton FlynnCelgene's CEO Talks New Approvals, Future OpportunitiesImportant stories from the biggest conference in biotech investing.
Feb 12, 2013 by Brenton FlynnDid AbbVie and Zoetis Add Value for Abbott Labs and Pfizer Shareholders?One looks like a winner, but the jury is still out for another
Feb 12, 2013 by Brenton FlynnArena Investors: You Need More Than a BlockbusterReaching $1 billion in annual sales won't cut it for Arena investors
Feb 11, 2013 by Brenton Flynn1 Must-Watch MAKO Surgical MetricOne important sales-driving metric to follow for surgical robotics investors.
Feb 11, 2013 by Brenton Flynn1 Must-Watch Intuitive Surgical MetricOne important sales-driving metric to follow for surgical robotics investors.
Feb 11, 2013 by Brenton Flynn1 Powerhouse Drug in Celgene's PipelineCelgene discusses its potential powerhouse inflammation drug at this week's BIO CEO conference.
